Acute Radiation Syndrome (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Acute radiation syndrome (ARS) is a complex of syndromes developed in humans due to short-duration whole-body exposure to ionizing radiation with doses higher than 0.7–1.0 Gy. The prodromal phase occurs within hours of exposure and may last up to 2 days. The latent phase is a transitional period in which the patient is asymptomatic. This may last as long as three weeks but is much shorter with higher radiation exposures. The illness phase produces overt clinical manifestations, including infection because of leukopenia, bleeding from thrombocytopenia, diarrhea, electrolyte imbalances, altered mental status, and shock. The death or recovery phase often occurs over weeks or months. Bone marrow syndrome (dose from 0.7 to 10.0 Gy), gastrointestinal syndrome (above 8.0 Gy), cardiovascular syndrome (above 20.0 Gy), central nervous system (or neurological) syndrome (above 80.0 Gy), and cutaneous (skin) syndrome (above 10.0 Gy)

·       As per Thelansis’ research which encompasses both the secondary and primary research findings, the prevalence of ARS varies between 1.3 to 8.4 /1,000,000 in different countries.

DM1 is categorized into four subtypes: congenital, childhood, classic, and minimal/late-onset.

Thelansis’s “Acute Radiation Syndrome (ARS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Radiation Syndrome (ARS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Acute Radiation Syndrome (ARS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acute Radiation Syndrome (ARS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Acute Radiation Syndrome (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034